Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 15/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651498 | 0.93 | HPGD (0.56) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL6752588 | 0.92 | HPGD (0.54) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2649744 | 0.92 | HPGD (0.60) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2651819 | 0.91 | HPGD (0.55) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL7241895 | 0.91 | HPGD (0.56) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL5813161 | 0.90 | HPGD (0.52) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2654761 | 0.90 | HPGD (0.53) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2647587 | 0.87 | FGFR1 (0.68) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2662138 | 0.85 | FGFR1 (0.46) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2944419 | 0.85 | HPGD (0.58) | HPGDFGFR1ALDH1A1NPC1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | GABRA1, GABRA2, GABRA4 | HPGD 1806/4885FGFR1 3464/4885ALDH1A1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.